Prevalence and Clinical Determinants of Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation Before Pulmonary Vein Isolation

详细信息    查看全文

• 作者：Makiko Nishikii-Tachibana ; MD ; Nobuyuki Murakoshi ; MD ; PhD ; ^{n.murakoshi@md.tsukuba.ac.jp" class="auth_mail" title="E-mail the corresponding author} ; Yoshihiro Seo ; MD ; PhD ; DongZhu Xu ; MD ; PhD ; Masayoshi Yamamoto ; MD ; PhD ; Tomoko Ishizu ; MD ; PhD ; Akiko Atsumi ; MD ; PhD ; Tomoko Machino-Ohtsuka ; MD ; PhD ; Kenji Kuroki ; MD ; PhD ; Hiro Yamasaki ; MD ; PhD ; Miyako Igarashi ; MD ; PhD ; Yukio Sekiguchi ; MD ; PhD ; Kazutaka Aonuma ; MD ; PhD
• 刊名：The American Journal of Cardiology
• 出版年：2015
• 出版时间：1 November 2015
• 年：2015
• 卷：116
• 期：9
• 页码：1368-1373
• 全文大小：696 K

文摘

The CHADS₂ score is considered a reliable predictor of stroke/thromboembolism risk in patients with atrial fibrillation (AF). However, thromboembolism can occasionally occur even in patients with AF with low CHADS₂ score (CHADS₂ score = 0 or 1). To investigate the incidence and predictors of left atrial appendage (LAA) thrombus (LAAT) formation in patients with AF, we studied consecutive 543 Japanese patients with AF who underwent transesophageal echocardiography before pulmonary vein isolation from 2008 to 2012. All patients were treated with anticoagulation therapy with warfarin, and their clinical and echocardiographic characteristics were evaluated. LAATs were observed in 35 (6.4%) of 543 patients, and the prevalence was clearly correlated with the patient's CHADS₂ scores. Of 338 patients with low CHADS₂ score, LAATs were observed in 7 patients (2.1%). By multivariate analysis, increased left atrial volume (≥50 ml), decreased ejection fraction (<56%), and increased brain natriuretic peptide level (>75 pg/ml) were significantly associated with increased prevalence of LAATs, even in patients with low CHADS₂ score. Accordingly, we proposed a new scoring system to predict LAAT (left atrial volume ≥50 ml: score 2; ejection fraction <56%: score 1; brain natriuretic peptide >75 pg/ml: score 1). Patients with a score ≥2 have a greater risk of LAAT, whereas all patients with score ≤1 have no LAATs. Our scoring system is useful for evaluation of the risk of LAAT in patients with AF even with low CHADS₂ score.